Welcome to our dedicated page for Scynexis news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis stock.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company developing antifungal medicines based on its proprietary triterpenoid antifungal platform known as "fungerps." News about SCYNEXIS frequently centers on clinical data, regulatory interactions, collaborations, and its exclusive license agreement with GSK for ibrexafungerp, the active ingredient in the FDA-approved product BREXAFEMME for vulvovaginal candidiasis and reduction in the incidence of recurrent VVC.
On this page, readers can follow company announcements related to the development of next-generation fungerps, including SCY-247, which SCYNEXIS describes as a second-generation triterpenoid antifungal under clinical and preclinical evaluation for invasive fungal infections. Recent updates have highlighted positive Phase 1 single and multiple ascending dose results, preclinical data presented at scientific congresses, and plans for additional studies using both oral and intravenous formulations.
SCYNEXIS news also covers key events in its collaboration with GSK, such as the transfer of the BREXAFEMME New Drug Application, resolution of disagreements regarding the Phase 3 MARIO study in invasive candidiasis, and associated milestone or other payments. Regulatory and listing developments, including Nasdaq minimum bid price notices and extensions to regain compliance, are disclosed through company press releases and SEC filings.
Investors, clinicians, and researchers can use this news feed to review updates on clinical trial progress, antifungal data presentations, license agreement developments, and corporate milestones. Regularly checking this page helps users track how SCYNEXIS advances its fungerp platform, manages its partnership with GSK, and responds to regulatory and market requirements.
On February 25, 2021, SCYNEXIS (NASDAQ: SCYX) announced that CEO Marco Taglietti will speak at Maxim Group's Late Stage Innovations in Women's Health event, scheduled for March 4, 2021, at 11:00 AM ET. Taglietti will provide insights on Brexafemme, an oral antifungal candidate currently under FDA review for treating vaginal yeast infections, with a PDUFA action date set for June 1, 2021. This highlights SCYNEXIS's commitment to addressing drug-resistant infections through innovative therapies.
SCYNEXIS has partnered with Amplity Health to enhance the commercial launch of Brexafemme, an antifungal treatment for vaginal yeast infections, which is set for FDA review with a PDUFA date of June 1, 2021. This partnership will utilize Amplity's sales capabilities while deferring some commercialization costs for the first two years. Brexafemme, an innovative oral treatment, aims to address the unmet needs in women's health, particularly as existing treatments may not be effective for many patients. SCYNEXIS is well-positioned financially, with a cash runway into 2023.
SCYNEXIS has entered a strategic partnership with Hansoh Pharmaceutical for ibrexafungerp, a broad-spectrum antifungal. Under this licensing agreement, SCYNEXIS will receive $122 million, including a $10 million upfront payment and low double-digit royalties. The collaboration enhances SCYNEXIS's cash runway into 2023 and preserves its commercial rights outside Greater China. Ibrexafungerp, currently pending FDA review for vaginal yeast infections, aims to address the rising antifungal resistance, showcasing its potential in combating serious fungal infections.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced the closing of its public offering of common stock, pre-funded warrants, and warrants, raising total gross proceeds of $85 million. The offering price was set at $6.25 per share and $6.249 per pre-funded warrant. In total, 8,340,000 shares of common stock and 5,260,000 pre-funded warrants were issued, along with warrants for 13,600,000 additional shares. The exercise price for the Series 1 and Series 2 warrants is $7.33 and $8.25 respectively. The funds raised are intended for advancing the company's clinical programs and general corporate purposes.
SCYNEXIS, Inc. (NASDAQ: SCYX) has priced its public offering of common stock, pre-funded warrants, and warrants at $6.25 per share, aiming for gross proceeds of approximately $85 million. The offering includes 8,390,000 shares and 5,210,000 pre-funded warrants, along with two series of warrants for an aggregate of 13,600,000 shares. The Series 1 warrants have a one-year term with an exercise price of $7.33, while Series 2 warrants have a three-and-a-half-year term at $8.25. This follows a shelf registration filed with the SEC in September 2020.
SCYNEXIS, Inc. (NASDAQ: SCYX) has announced a public offering of shares and warrants for its common stock. The offering, managed by Guggenheim Securities, LLC and Cantor Fitzgerald & Co., is contingent on market conditions. The company will sell all shares and warrants, with pre-funded warrants available for specific purchasers. A shelf registration statement was filed with the SEC on September 11, 2020. The final offering terms will be detailed in a prospectus supplement. SCYNEXIS focuses on innovating treatments for drug-resistant infections.
SCYNEXIS has announced approval from health authorities to initiate Phase 1 trials for the intravenous formulation of ibrexafungerp, targeting dosing in healthy volunteers by Q1 2021. Additionally, a new interim analysis of the ongoing Phase 3 studies (FURI and CARES) is set for the same timeframe, with an increase in the patient dataset from 41 to 84. This analysis will yield the first clinical trial data against Candida auris, a multidrug-resistant fungus. Ibrexafungerp is positioned to be the first new antifungal class in over 20 years, with both IV and oral formulations planned.
SCYNEXIS, Inc. has received Priority Review status from the FDA for its New Drug Application (NDA) for ibrexafungerp, aimed at treating vulvovaginal candidiasis (VVC). The PDUFA target action date is set for June 1, 2021. The FDA will not hold an advisory committee meeting for this application. Supported by two positive Phase 3 studies, ibrexafungerp could change the antifungal treatment landscape, potentially capturing a significant share of the market, estimated at over 16 million prescriptions annually.
SCYNEXIS, a biotechnology firm focused on innovative medicines for drug-resistant infections, announced its participation in key healthcare conferences. The Piper Sandler 32nd Annual Virtual Healthcare Conference runs from November 23 to December 3, 2020, allowing registered attendees to access presentations from 8:00 a.m. to 5:00 p.m. ET. Additionally, SCYNEXIS will join a panel discussion at Evercore ISI’s HealthCONx Conference on December 2, 2020, from 11:20 a.m. to 12:05 p.m. ET, addressing critical fungal infection needs. Webcast recordings will be available on their website for 30 days.
SCYNEXIS submitted a New Drug Application (NDA) for ibrexafungerp, targeting vulvovaginal candidiasis (VVC), with approval expected in mid-2021. The company estimates over 15 million antifungal prescriptions for VVC annually. Enrollment continues in the Phase 3 CANDLE study, alongside studies for serious fungal infections. Financially, SCYNEXIS reported a net income of $0.9 million for Q3 2020, a significant recovery from a net loss of $7.9 million in Q3 2019. Cash and equivalents totaled $29.5 million as of September 30, 2020.